Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada

Knight Therapeutics and SIFI S.p.A

MONTREAL, Oct. 23, 2019 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian Eye Care company, today announced that Health Canada has approved NETILDEX® for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical therapy to reduce the risk of bacterial infection is appropriate.  Knight and SIFI entered into an exclusive Canadian agreement NETILDEX® in August 2016.
“We are excited about the approval of NETILDEX® in Canada, providing patients with a new antibiotic with a well-established corticosteroid” said Jonathan Ross Goodman, Chief Executive Officer of Knight.“We are thrilled with the Canadian approval for NETILDEX®,” said Mr. Fabrizio Chines, Chairman and Chief Executive Officer of SIFI. “This approval will broaden the global availability of NETILDEX®, providing access to Canadian patients and physicians to our differentiated product.”About NETILDEX®About SIFI S.p.A.Forward-Looking StatementFor further information, please contact:Knight Therapeutics Inc.
Samira Sakhia
President and Chief Financial Officer
T: 514-678-8930
F: 514-481-4116
info@gudknight.com
www.gud-knight.com  
Press & Communication SIFI
press@sifigroup.com +393336999669 / Ada Puglisi 0039 095 7922145 

CBJ Newsmakers

Recommended
Endeavour Silver Reports Infill Drill Results for the Parral Project in Chihuahua, Mexico Including 308 gpt Silver over 11Roadman Investments Reviews Q3 Corporate Initiatives And Provides Q4 Guidance